Ignite Creation Date:
2024-05-06 @ 8:12 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06299540
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2024-03-01
Brief Title:
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
Sponsor:
Janssen Cilag SAS
Organization:
Janssen Cilag SAS
Study Overview
Official Title:
Benefits of an Individual Physical Activity Intervention on Health-related Quality of Life in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib in Real-life Practice
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
QOLIBRI
Brief Summary:
The purpose of this study is to assess the impact of an individual physical activity intervention IPAI on health-related quality of life HRQoL in participants with first line or relapsed chronic lymphocytic leukemia CLL initiating ibrutinib in a routine clinical practice setting HRQoL will be measured using functional assessment of cancer therapy - general scale FACT-G
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 54179060CLL4033 | OTHER | Janssen-Cilag France | None |